Categories: Health

Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Ricas Coyol Free Trade Zone

BROOKLYN PARK, MN, April 13, 2026 (GLOBE NEWSWIRE) — Switchback Medical, a medical device contract development and manufacturing organization (CDMO), announced it has signed a lease for a new 18,000-square-foot facility in the Coyol Free Trade Zone in Costa Rica, marking a significant expansion of its global manufacturing and development capabilities. The site will include a 3,500-square-foot cleanroom.

The facility is designed to support medical device component manufacturing with the ability to expand capabilities over time. Development and product transfers will start immediately, followed by manufacturing and ISO 13485 certification later this year. Switchback will be supporting both existing customer programs and new development initiatives.

The Coyol facility represents the first phase of Switchback’s broader Costa Rica strategy, with a second, larger site planned in the Evolution Free Trade Zone, expected to open in 2027. Together, these facilities will create a scalable footprint to support near-term manufacturing demand and long-term growth.

This expansion reflects a strategic investment in Costa Rica’s growing medtech ecosystem, offering Free Trade Zone benefits, a skilled workforce, and proximity to both U.S. markets and local customers. Driven by increasing demand for scalable manufacturing and R&D/PD support, the new facility will enhance Switchback’s ability to support development programs and high-volume production while improving cost efficiency for customers.

Switchback will leverage its design expertise to provide quick-turn development support for in-country R&D and PD teams in Costa Rica, helping to accelerate innovation within the region’s growing medtech sector. By combining responsive development capabilities with scalable manufacturing, Switchback is uniquely positioned to support customers earlier in the product lifecycle—an approach that sets it apart from traditional manufacturing-focused operations in the region.

“Our Coyol facility allows us to quickly deliver critical components such as extrusions, braided shafts, and more, while we continue building out our Evolution facility, which will serve as our top-level assembly production site in Costa Rica,” said Brady Hatcher, CEO of Switchback Medical. “Together, these capabilities enable us to support customers from early development through full-scale manufacturing, both locally and globally.”

Over the next decade, the Coyol and Evolution facilities are expected to expand Switchback’s role in interventional device manufacturing, supporting additional development programs, manufacturing transfers, and scaled production. The expansion will initially focus on thermoplastic extrusion and precision components, with future plans to expand into advanced extrusion technologies and full device production.

About Switchback Medical
Switchback offers single-source solutions for contract design and manufacturing needs. From component design and manufacturing to full device packaging & sterilization, Switchback simplifies the supply chain to reduce development costs and overall time to market.

They serve all minimally invasive interventional device markets and have special interests and capabilities in neurovascular and structural heart applications. Design and manufacturing capabilities are not limited to, but include balloon catheters, complex delivery systems, and biomedical textile devices. Learn more at https://switchbackmedical.com/ and connect on LinkedIn at https://www.linkedin.com/company/switchback-medical  

Media Contact
Allie Hatcher
Marketing Specialist
allie.hatcher@switchbackmedical.com
612-615-1155

GlobeNews Wire

Recent Posts

Milken Institute Global Conference 2026 Set to Open Tomorrow in Beverly Hills with KFSH Participation

BEVERLY HILLS, Calif., May 02, 2026 (GLOBE NEWSWIRE) -- The Milken Institute Global Conference 2026…

3 hours ago

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

May 01, 2026 17:05 ET  | Source: Eupraxia Pharmaceuticals Inc. VANCOUVER, British Columbia, May 01,…

3 hours ago

Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

MINNEAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company…

3 hours ago

Crypto News Today: AlphaPepe Presale Nears $1.1M Raised Whilst Cardano Price Prediction Targets $5.00

MONACO CITY, Monaco, May 02, 2026 (GLOBE NEWSWIRE) -- AlphaPepe is nearing $1.1 million in…

21 hours ago

Steel Power Unveiled: Is SteelPower Male Enhancement Formula Legit? Read Steel Power Supplement Report!

New York City, NY, May 02, 2026 (GLOBE NEWSWIRE) -- Steel Power has quickly emerged…

21 hours ago

HaloGrow Analyzed: Why Is Halo Grow Hair Growth Spray Trending In The United States?

New York City, NY, May 02, 2026 (GLOBE NEWSWIRE) -- Understanding the amazingly consistent pattern…

21 hours ago